Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
References
Abbreviations
Hematology
Biosimilars
Global Health
tropifexor, licogliflozin - FXR agonist and SGLT 1/2 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04065841 ELIVATE (CLJN452D12201C)
Non-alcoholic steatohepatitis (NASH)
Phase 2
380
Proportion of patients with resolution of NASH and no worsening of fibrosis OR
improvement in fibrosis by at least one stage without worsening of NASH at Week
48 compared with baseline
Arm A: combination therapytropifexor + licogliflozin
Arm B: tropifexor monotherapytropifexor + licogliflozin placebo
Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo
Arm D: licogliflozin placebo + tropifexor placebo
Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver
fibrosis
Target Patients
Read-out Milestone(s)
Publication
2024
2025
68 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation